Literature DB >> 17720313

Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease.

Masaaki Waragai1, Masaaki Nakai, Jianshe Wei, Masayo Fujita, Hideya Mizuno, Gilbert Ho, Eliezer Masliah, Hiroyasu Akatsu, Fusako Yokochi, Makoto Hashimoto.   

Abstract

DJ-1 is a multifunctional protein whose loss of function by gene mutations may play a causative role for familial Parkinson's disease (PD). A recent study has shown that the expression of this molecule is upregulated in both brains and cerebrospinal fluids (CSF) in various neurological disorders, including sporadic PD, Alzheimer's disease (AD) and stroke, raising a possibility that DJ-1 could be a potential biomarker for these diseases. In this context, the main objective of the present study was to determine if DJ-1 was increased in the plasma of PD patients. For this purpose, blood plasma samples collected from sporadic PD patients, dementia with Lewy bodies (DLB) and healthy age-matched controls were analyzed by immunoblotting and enzyme-linked immunosorbent assay. The results showed that the plasma DJ-1 levels in PD (n=104) were higher than those in control (n=80) (p<0.05). Moreover, the plasma DJ-1 levels in the advanced stage of PD (n=52, Yahr III-IV) were higher than those in the early stage of PD (n=52, Yahr I-II) (p<0.05), demonstrating that the plasma DJ-1 was correlated with the disease severity in PD. Plasma DJ-1 levels were also significantly higher in DLB (n=30) compared with both controls and early stage of PD (p<0.01). Taken together, these results suggest that the plasma DJ-1 could be a useful biomarker for the evaluation of the disease severity in PD and possibly in other Lewy body diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720313     DOI: 10.1016/j.neulet.2007.08.010

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  28 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 2.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

Review 3.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 4.  Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.

Authors:  Eugene M Cilento; Lorrain Jin; Tessandra Stewart; Min Shi; Lifu Sheng; Jing Zhang
Journal:  J Neurochem       Date:  2019-01-31       Impact factor: 5.372

5.  Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.

Authors:  Min Shi; Cyrus P Zabetian; Aneeka M Hancock; Carmen Ginghina; Zhen Hong; Dora Yearout; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; James B Leverenz; Jing Zhang
Journal:  Neurosci Lett       Date:  2010-06-09       Impact factor: 3.046

6.  DJ-1/PARK7, But Not Its L166P Mutant Linked to Autosomal Recessive Parkinsonism, Modulates the Transcriptional Activity of the Orphan Nuclear Receptor Nurr1 In Vitro and In Vivo.

Authors:  Lingling Lu; Shasha Zhao; Ge Gao; Xiaohong Sun; Huanying Zhao; Hui Yang
Journal:  Mol Neurobiol       Date:  2016-02-12       Impact factor: 5.590

7.  Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity.

Authors:  Nirit Lev; Yael Barhum; Tali Ben-Zur; Eldad Melamed; Israel Steiner; Daniel Offen
Journal:  J Mol Neurosci       Date:  2013-03-28       Impact factor: 3.444

Review 8.  Biomarkers of Parkinson's disease: current status and future perspectives.

Authors:  Jian Wang; Jake G Hoekstra; Chuantao Zuo; Travis J Cook; Jing Zhang
Journal:  Drug Discov Today       Date:  2012-09-11       Impact factor: 7.851

Review 9.  Biomarker discovery in neurodegenerative diseases: a proteomic approach.

Authors:  Min Shi; W Michael Caudle; Jing Zhang
Journal:  Neurobiol Dis       Date:  2008-09-26       Impact factor: 5.996

Review 10.  Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.

Authors:  Ilan Halperin; Micaela Morelli; Amos D Korczyn; Moussa B H Youdim; Silvia A Mandel
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.